On Nov 08, major Wall Street analysts update their ratings for $Amicus Therapeutics (FOLD.US)$, with price targets ranging from $15 to $21.
Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and maintains the target price at $17.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $19 to $21.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $20.
Guggenheim analyst Debjit Chattopadhyay maintains with a buy rating, and adjusts the target price from $13 to $15.
Furthermore, according to the comprehensive report, the opinions of $Amicus Therapeutics (FOLD.US)$'s main analysts recently are as follows:
Amicus' third quarter revenues surpassed expectations, with significant sales of Galafold and additional purchase order sales highlighted by the analyst. Post-results, the model was updated to reflect the latest quarter and guidance, with adjustments made for the discount year and an increase in cost of goods sold, correlating with management's comments on inventory expenses for P+O.
Following a quarter with sales surpassing consensus, coupled with an upward revision of the fiscal year guidance for Galafold and Pombiliti, the narrative surrounding Amicus may prove to be quite attractive to various strategic acquirers in 2025.
Here are the latest investment ratings and price targets for $Amicus Therapeutics (FOLD.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
